Cancer Family
Rare Neoplasm
CI-CAN-00000048Explore in graph →
Non-malignant116 active trials3 approved drugs7 evidence items
- NCIt
- C7201
Loading cancer entity…
Cancer Family
CI-CAN-00000048Explore in graph →
Clinical trials
361 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome | not yet recruiting | Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07744724 | Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL | not yet recruiting | Phase 2 | 48 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 |
| clinicaltrials |
| NCT07744737 | Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL | not yet recruiting | Phase 2 | 34 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07744750 | Pirtobrutinib+Sonrotoclax(PS) Regimen in the Treatment of B-Cell Lymphoma | not yet recruiting | Phase 2 | 40 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07677813 | Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma | not yet recruiting | Phase 2 | 66 | Ou Bai, MD/PHDOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07552324 | Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP | not yet recruiting | Phase 2 | 28 | Ruijin HospitalOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT07326371 | Glofitamab Combined With CAR-T Therapy in R/R DLBCL | not yet recruiting | Phase 2 | 24 | Ruijin HospitalOTHER | 0 | Jan 8, 2026 | clinicaltrials |
| NCT07307053 | Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) | not yet recruiting | Phase 1 / Phase 2 | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07231250 | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | not yet recruiting | Phase 2 | 40 | Li ZhimingOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07034508 | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 | not yet recruiting | Phase 2 | 134 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06871527 | Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06819605 | Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma(NETCAM-RCT) | not yet recruiting | Phase 2 / Phase 3 | 46 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 0 | Feb 11, 2025 | clinicaltrials |
| NCT06748508 | Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer(FDZL-GC003) | not yet recruiting | Phase 2 | 141 | Fudan UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06692491 | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS(SPRING) | not yet recruiting | Phase 2 | 200 | Peking University Shenzhen HospitalOTHER | 0 | Nov 18, 2024 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials